Abstracts tagged "Epidemiology"

Abstract Number: 0490 • ACR Convergence 2024
Improvements in Peri-fracture Care in Rheumatoid Arthritis (RA) Have Offset Increased Mortality
Owen Taylor-Williams¹, Johannes Nossent² and Charles Inderjeeth³, ¹University of Western Australia, Perth, Western Australia, Australia, ²University of Western Australia, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia, ³SCGH and OPH Group & University of Western Australia, Perth, Western Australia, Australia
Background/Purpose: Hip or pelvis fractures (HOP) are common osteoporotic fractures (OP) with significant risks of medical complications, placement into care, reduced quality of life and…
Abstract Number: 0977 • ACR Convergence 2024
Vaccine Effectiveness and Safety of Recombinant Zoster Vaccine (RZV) in Rheumatoid Arthritis (RA) Patient Populations Aged 50 Years and Older
Emily Rayens¹, Lina Sy¹, Lei Qian¹, Jun Wu¹, Bradley Ackerson¹, Yi Luo¹, Yanjun Cheng¹, Antony Lin¹, Zendi Solano¹, Justine De Jesus¹, Britta Amundsen¹, Ana Florea¹, Jen Ku¹, Elizabeth Chmielewski-Yee², Driss Oraichi², Harry Seifert², Huifeng Yun² and Hung-Fu Tseng¹, ¹Kaiser Permanente Southern California, Pasadena, CA, ²GSK, Rockville, MD
Background/Purpose: Individuals with rheumatoid arthritis (RA) are at higher risk of herpes zoster (HZ) compared to the general population. This interim analysis evaluated the vaccine…
Abstract Number: 1007 • ACR Convergence 2024
Demographic, Social, and Disease Factors Associated with Interstitial Lung Disease and Disease-Related Death in Dermatomyositis
Connor Buechler, Lindsey Wanberg, Nawang Singhe, Cody Rasner, Joseph McGrath, Ziou Jiang, Karen Baker-James and David Pearson, University of Minnesota, Minneapolis, MN
Background/Purpose: Dermatomyositis (DM) is associated with significant morbidity and mortality due to disease-related progressive interstitial lung disease (ILD) and malignancy. However, little is known about…
Abstract Number: 1201 • ACR Convergence 2024
Association of COVID-19 Vaccinations with Osteoarthritis Flares: A Case-Crossover Study
Minerva Nong¹, Colby Lewis V², Genna Braverman³, Vivian Bykerk³, Nathaniel Hupert², Medha Barbhaiya³ and Lisa Mandl³, ¹Hospital for Special Surgery, Tampa, FL, ²Weill Cornell Medicine, New York, NY, ³Hospital for Special Surgery, New York, NY
Background/Purpose: People with osteoarthritis (OA) commonly experience periods of increased pain and stiffness (“flares”), which can be distressing and disabling. Despite the prevalence of OA…
Abstract Number: 1508 • ACR Convergence 2024
Clinical Characteristics and Prognosis of Late-onset Systemic Lupus Erythematosus in 305 Japanese Patients
Yuko Shirota¹, Misa Oguma², Ryo Kuwata³, Yumi Tajima⁴, Yumiko Oka⁵, Miki Takeshita², Takao Kodera² and Tomonori Ishii², ¹Tohoku University Hospital / Department of Hematology and Rheumatology, Sendai, Japan, ²Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai, Japan, ³National Center for Global Health and Medicine / Division of Rheumatic Diseases, Shinjyuku, Tokyo, Japan, ⁴Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai, Miyazaki, Japan, ⁵Tohoku Medical and Pharmaceutical University / Department of Hematology and Rheumatology, Sendai
Background/Purpose: In recent years, the number of older patients with systemic lupus erythematosus (SLE) in Japan has been increasing, with particular attention to those developing…
Abstract Number: 1881 • ACR Convergence 2024
Cross-State Comparative Assessment of Burden of Rheumatoid Arthritis in the United States and It’s Trend from 1990-2021: A Benchmarking Analysis for the Global Burden of Disease Study 2022
Rafael Sanchez-Dopazo,¹, Eva Kalra², Shadi Abuhashem³, abobakr Saleh⁴, Khalid Faris⁵, Rutvik Raval⁶, Shamitha Hejmadi⁶, Lovekumar Vala⁷, Riya Dhadhal⁸ and Hardik Desai⁹, ¹Larkin Community Hospital Palm Springs Campus, Hialeah, FL, ²Trident Medical Cente, Charleston, SC, ³Alquds University, Jerusalem, West Bank, Palestine, 9458123, Gaza, Palestinian Territories, ⁴kasr alainy Medical School - Cairo University,Egypt/ 11956, Cairo, Egypt, ⁵Studied in Al-Quds university, Palestine, Gaza, Palestinian Territories, ⁶B.J. Medical College, Ahmedabad, India, ⁷Department of Internal Medicine, Shantabaa Medical College and General Hospital, Amreli, Gujarat, India, 365601, Amreli, Gujarat, India, ⁸SMIMER Hospital & Medical College, Surat, Gujarat, India, ⁹Gujarat Adani Institute of Medical Sciences, Bhuj, India
Background/Purpose: The burden of Rheumatoid Arthritis (RA) in the United States is considerable, both in terms of its prevalence and the economic costs it incurs.…
Abstract Number: 1906 • ACR Convergence 2024
Bayesian Algorithm to Identify Osteoarthritis in Administrative Health Data Without Requiring Chart Review
S. Reza Jafarzadeh¹, Sarah Tilley¹, Anup Arvind¹ and David Felson², ¹Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ²Boston University, Boston, MA
Background/Purpose: Osteoarthritis (OA) is the most prevalent arthritis and a significant contributor to Years Lived with Disability. Administrative health data are widely used to study…
Abstract Number: 2322 • ACR Convergence 2024
Predictors of Work Impairment and Absence Amongst People with Psoriatic Arthritis (PsA) – Evidence from the British Society for Rheumatology PsA Register (BSR-PsA)
Lili Xu¹, Gareth Jones¹, Ovidiu Rotariu¹, Philip S. Helliwell², Stefan Siebert³, Rosemary Hollick¹ and Gary Macfarlane¹, ¹University of Aberdeen, Aberdeen, United Kingdom, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK, Leeds, United Kingdom, ³School of Infection and Immunity, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: People with PsA often report that their condition affects their ability to work. Poor work outcomes, such as work impairment, absence or leaving work,…
Abstract Number: 2556 • ACR Convergence 2024
A Multi-center Study of Associations Between Neighborhood-Level Child Opportunity, Initial Disease Severity and Acute Care Utilization Among Children with SLE
Joyce Chang¹, Jessica Liu¹, Emily Smitherman², Pooja Patel³, Gabrielle Alonzi¹, Gabrielle Morgan⁴, Livie Timmerman⁵, Laura Berbert⁶, Edie Weller¹, Karen Costenbader⁷ and Mary Beth Son⁸, ¹Boston Children's Hospital, Boston, MA, ²University of Alabama at Birmingham, Birmingham, AL, ³Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁴Ann & Robert H. Lurie Children's Hospital of Chicago and Northwestern University Feinberg School of Medicine, Chicago, IL, ⁵University of Alabama at Birmingham, Gardendale, AL, ⁶Boston Children's Hospital, Belmont, MA, ⁷Brigham and Women's Hospital/ Harvard Medical School, Boston, MA, ⁸Boston Children's Hospital, Brookline, MA
Background/Purpose: Child opportunity is defined as the neighborhood resources and conditions that promote healthy childhood development. We determined whether low neighborhood-level opportunity associates with more…
Abstract Number: 0145 • ACR Convergence 2024
Community Mobility in a Diverse Cohort of Individuals with Systemic Lupus Erythematosus
Leila Milanfar¹, Jinoos Yazdany², Amanda Eudy³, Courtney Hoge⁴, Charmayne M. Dunlop-Thomas⁵, Patti Katz⁶ and Laura Plantinga⁷, ¹University of California San Francisco, San Francisco, CA, ²UCSF, San Francisco, CA, ³Duke University, Raleigh, NC, ⁴Emory University, Atlanta, GA, ⁵Emory University School of Medicine, Department of Medicine, Division of Rheumatology, Atlanta, GA, ⁶UCSF, San Rafael, CA, ⁷University of California, San Francisco, San Francisco, CA
Background/Purpose: Measurement of the extent to which individuals move throughout their community and participate in social activities (“community mobility”) can provide a snapshot of how…
Abstract Number: 0280 • ACR Convergence 2024
Trends in Management and Consultations for Gout: A Study of 18 Million Adults Using the OpenSAFELY Platform
Mark Russell¹, Jon Massey², Edward Roddy³, Brian MacKenna⁴, Seb Bacon⁴, Ben Goldacre⁴, Colm Andrews⁴, George Hickman⁴, Amir Mehrkar², Arti Mahto⁵, Andrew Rutherford⁶, Samir Patel¹, Maryam Adas⁷, Edward Alveyn⁷, deepak Nagra¹, Katie Bechman⁷, Joanna Ledingham⁸, Joanna Hudson⁹, Sam Norton¹, Andrew Cope⁷ and James Galloway¹⁰, ¹King's College London, London, England, United Kingdom, ²University of Oxford, Oxford, England, United Kingdom, ³Keele University, Keele, England, United Kingdom, ⁴University of Oxford, Oxford, United Kingdom, ⁵King's College Hospital NHS Foundation Trust, London, United Kingdom, ⁶King's College Hospital NHS Foundation Trust, London, England, United Kingdom, ⁷King's College London, London, United Kingdom, ⁸Portsmouth Hospitals University NHS Trust, Portsmouth, United Kingdom, ⁹King's College London, King's College London, United Kingdom, ¹⁰Centre for Rheumatic Diseases, King's College London, London, United Kingdom
Background/Purpose: Data from before the COVID-19 pandemic had shown persistently poor care for people with gout in many countries worldwide. Whether this was further exacerbated…
Abstract Number: 0503 • ACR Convergence 2024
Use of Janus Kinase Inhibitors Before and After European Medicines Agency Safety Recommendations
Patrick-Pascal Strunz¹, Linus Maximilian Risser², Matthias Englbrecht³, Torsten Witte⁴, Matthias Froehlich⁵, Marc Schmalzing⁶, Michael Gernert⁷, Peter Bartz-Bazzanella⁸, Sebastian Hueper⁹, Cay von Der Decken¹⁰, Georg Gauler¹¹, Susanna Spaethling-Mestekemper¹², Christoph Kuhn¹³, Kirsten Karberg¹⁴, Wolfgang Vorbrueggen¹⁵, Martin Welcker¹⁶ and Stefan Kleinert¹⁷, ¹University hospital of Wuerzburg, Wuerzburg, Germany, ²Hannover Medical School, Hannover, Germany, ³Freelance Healthcare Data Scientist, Eckental, ⁴Dept of Immunology and Rheumatology, Hannover, Germany, ⁵Uniklinikum Wuerzburg, Medizinische Klinik II, Wuerzburg, Germany, ⁶University Hospital Wuerzburg, Würzburg, Germany, ⁷Medicine II, Division Rheumatology/Clinical Immunology, University Hospital of Wuerzburg, Wuerzburg, ⁸Rhein-Maas Klinikum, Wuerselen, Germany, ⁹Praxis für Rheumatologie und Osteologie, Hildesheim, Germany, ¹⁰Klinik für Internistische Rheumatologie, Rhein-Maas-Klinik Wuerselen, Würselen, ¹¹rheumapraxis, Osnabrück, Germany, ¹²Rheumapraxis Muenchen, Muenchen, Germany, ¹³Praxis für Rheumatologie, Karlsruhe, Germany, ¹⁴Rheumatologisches Versorgungszentrum Steglitz, Berlin, Germany, ¹⁵RheumaDatenRhePort GbR, Wuerselen, Germany, ¹⁶Medizinisches Versorgungszentrum für Rheumatologie Dr. M. Welcker GmbH, Planegg, Germany, ¹⁷Praxisgemeinschaft Rheumatologie - Nephrologie (PGRN), Erlangen, Germany
Background/Purpose: Safety recommendations for Janus kinase inhibitors (JAKi) issued by the European Medical Agency (EMA) in 2023 could potentially influence prescription patterns for drugs used…
Abstract Number: 0139 • ACR Convergence 2023
Systemic Vasculitides in Portugal and Brazil: Preliminary Results from the Reuma.pt/vasculitis Registry
Mariana de Aguiar¹, Alexandre wagner Silva de Souza², Joana Martinho³, Adriana Carones⁴, Ana Beatriz Bacchiega de Freitas⁵, Ana Catarina Duarte⁶, Ana Filipa Águeda⁷, Camila Souto Oliveira Elias⁸, Catarina Cortesão⁹, Catarina Soares¹⁰, Carla Macieira¹¹, Carlos Eduardo Garcez Teixeira¹², Daniela Peixoto¹³, Duarte Vinha³, Estela Nogueira³, Fabricia Simil¹⁴, Francisca Guimarães¹³, Frederico Rajão Martins¹⁵, Gilda Ferreira¹⁶, Helena Assunção⁴, Heloisa Rulff⁸, Jorge Pestana Lopes⁶, José Costa³, Julia Medeiros¹⁷, Lilian Santos Porto¹⁸, Luiz Felipe Adsuara¹⁷, Manuella Ochtrop⁸, Maria João Gonçalves¹⁹, Mariana Diz Lopes²⁰, Matheus Vieira²¹, Nikita Khmelinskii¹¹, Rita Torres²², Sarah Neaime¹, Vitor Teixeira²³, Zoraida Sachetto¹² and Cristina Ponte²⁴, ¹Universidade Federal de São Paulo (UNIFESP), São Paulo, Brazil, ²Division of Rheumatology, Medical School, Universidade Federal de São Paulo, São Paulo, Brazil, ³Centro Hospitalar Universitario Lisboa Norte, Lisboa, Portugal, ⁴Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal, ⁵Faculdade de Ciências da Saúde de Barretos, Barretos, Brazil, ⁶Hospital Garcia de Orta, Almada, Portugal, ⁷Centro Hospitalar Universitário Cova da Beira, Covilhã, Portugal, ⁸Universidade Estadual do Rio de Janeiro, Rio de Janeiro, Brazil, ⁹Instituto Português de Reumatologia, Lisboa, Portugal, ¹⁰Centro Unidade Local de Saúde do Alto Minho, Viana do Castelo, Portugal, ¹¹Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ¹²Universidade Estadual de Campinas, Campinas, Brazil, ¹³Centro Unidade Local de Saúde do Alto Minho, Ponte de Lima, Portugal, ¹⁴Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, ¹⁵Department of Rheumatology, University Hospital Centre of Algarve, Faro, Portugal, ¹⁶Federal University of Minas Gerais, Belo Horizonte, Brazil, ¹⁷Santa Casa de Misericórdia de São Paulo, São Paulo, Brazil, ¹⁸Santa Casa de Misericórdia de Belo Horizonte, Belo Horizonte, Brazil, ¹⁹Centro Hospitalar de Lisboa Ocidental, Lisboa, Portugal, ²⁰Centro Hospitalar Universitário de São João, Porto, Portugal, ²¹Universidade Federal de São Paulo; Universidade Federal do Rio de Janeiro, Rio de Janeiro, Brazil, ²²Hospital Egas Moniz, Lisboa, Portugal, ²³Hospital de Faro, CHUA, Lisbon, Portugal, ²⁴Department of Rheumatology, Centro Hospitalar Universitário Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisbon, Portugal; Rheumatology Research Unit, Instituto de Medicina Molecular, Faculdade de Medicina, Universidade de Lisboa, Centro Académico de Medicina de Lisboa, Lisbon, Portugal
Background/Purpose: The epidemiology of vasculitis varies widely across different geographic areas of the world which may be due to different ethnic and environmental factors. Brazil…
Abstract Number: 0477 • ACR Convergence 2023
Continuing TNFi After Pregnancy Diagnosis in Women with Chronic Rheumatic Inflammatory Diseases Is Not Associated with Worse Obstetrical or Infant Outcomes and Seems to Reduce Risk of Maternal Severe Infection: The Results of the Emulated Target Trial BioGRIC
Anna Molto¹, aya ajrouche², Diep Tran², Nathalie Costedoat-Chalumeau³, Elisabeth Elefant⁴, Vassilis Tsatsaris⁵, Jeanne Fresson⁶, Brigitte Bader-Meunier⁵, Bruno Fautrel⁷ and Florence Tubach², ¹HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ²Centre de pharmaco-épidémiologie de l'APHP, Paris, France, ³Inserm DR Paris 5, Paris, France, ⁴APHP, Paris, France, ⁵Paris-Cité University, Paris, France, ⁶CHU Nancy, Nancy, France, ⁷Sorbonne Université APHP, Paris, France
Background/Purpose: Many women with chronic rheumatic inflammatory diseases (CRID) stop tumor necrosis factor inhibitors (TNFi) treatment once pregnancy is confirmed to avoid potential adverse fetal…
Abstract Number: 0739 • ACR Convergence 2023
Major Adverse Cardiovascular Event and Venous Thromboembolism Risk Comparing Advanced Therapies Among Individuals with Axial Spondylarthritis and Psoriatic Arthritis
Sali Merjanah¹, Devin Driscoll², Christine Peloquin³, Jean liew³ and Maureen Dubreuil⁴, ¹Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ²Boston University/Boston Medical Center, Boston, MA, ³Boston University, Boston, MA, ⁴Department of Rheumatology, Boston University School of Medicine, Milton, MA
Background/Purpose: Individuals with axial spondyloarthritis (axSpA) and psoriatic arthritis (PsA) have increased cardiovascular risk compared to the general population, which is partly explained by systemic…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].